CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease.

@article{Woodson2006CD44AP,
  title={CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease.},
  author={Karen G Woodson and Keith J O'Reilly and David E. Ward and Jack Walter and Jeffrey C. Hanson and Elyse L. Walk and Joseph A. Tangrea},
  journal={Epigenetics},
  year={2006},
  volume={1 4},
  pages={183-6}
}
Up to 30% of men with clinically localized disease who receive radical prostatectomy develop a biochemical recurrence. Gene methylation in tumor tissue may distinguish men with aggressive cancer. This study evaluated methylation of GSTP1, RARb2, CD44 and PTGS2 with biochemical recurrence among 60 patients who underwent radical prostatectomy using logistic regression and Kaplan Meier time to event analysis. Methylation of GSTP1 and RARbeta2 was not associated with recurrence, however, CD44 and… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Similar Papers

Loading similar papers…